← 홈

프로그램 비교

검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일

현재 선택: 1

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

API CSV15행 · 1개 프로그램

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
CGTPhase 2
Rapcabtagene autoleucel (Rapcabtagene autoleucel)
Novartis Pharmaceuticals·ANCA Associated Vasculitis (AAV)
9 trials
Overview
Program
Rapcabtagene autoleucel
Overview
Company
Novartis Pharmaceuticals
Overview
Modality
CGT
Overview
Target
ANCA Associated Vasculitis (AAV)
Overview
Indication
ANCA Associated Vasculitis (AAV)
Overview
Phase
PHASE_2
Overview
Status
RECRUITING
PK/PD
Animal (cat.)
Unknown
PK/PD
Experiment
This syndrome tracked closely with the onset and resolution of immune-effector cell-associated neurotoxicity syndrome (ICANS), with close correlation between the severity of laboratory abnormalities, particularly extremely high ferritin (peak value: 81,540 μg/L), and clinical encephalopathy.
Toxicology
Animal (cat.)
Unknown
Toxicology
Major finding
Very unusual extremely high ferritin with cytokine release syndrome in a patient with hematological malignancy after experimental chimeric antigen receptor (CAR)-T-Cell therapy.. Chimeric antigen receptor (CAR) T cell therapy is an immunotherapy that has resulted in tremendous progress in the treatment of patients with B cell malignancies. However, significant toxicities may also be associated wit…
Toxicology
CRS
Reported
Clinical
Data Tier / Score
A · 21
Clinical
Program phase
PHASE_2
Clinical
Clinical sync
2026년 7월 13일 (1일 전)